GPLD1

Across TCGA pan-cancer cohorts, GPLD1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GPLD1 data layer compared with 22 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GPLD1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GPLD1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and COAD show a favorable association.

HNSC, UCEC, and UCS are the cancer types where GPLD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	IV	0.156	0.708	.007	12	view →
UCEC	DFS	Median	All	0.959	0.626	.019	8	view →
UCS	DFS	Median	All	0.126	0.523	.009	6	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
COAD	DFS	Median	All	1.000	0.774	.022	4	view →
SKCM	OS	Median	III,IV	0.179	0.721	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GPLD1–HNSC (OS)

Open the HNSC breakdown →